ENB 110e
Alternative Names: ENB-110eLatest Information Update: 26 Aug 2024
At a glance
- Originator EnnovaBio
- Class Anti-inflammatories; Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis
Most Recent Events
- 31 Jul 2024 Preclinical trials in Non-alcoholic steatohepatitis in China (Unspecified) prior to July 2024 (EnnovaBio pipeline, July 2024)
- 31 Jul 2024 Preclinical trials in Primary biliary cirrhosis in China (Unspecified) prior to July 2024 (EnnovaBio pipeline, July 2024)
- 31 Jul 2024 Preclinical trials in Primary sclerosing cholangitis in China (Unspecified) prior to July 2024 (EnnovaBio pipeline, July 2024)